| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -27,909 | - |
| Amortization of debt discount and issuance costs | 143 | 97 |
| Amortization of premium on short-term investments | 0 | 0 |
| Depreciation expense | 301 | 210 |
| Stock-based compensation expense | 3,786 | 2,610 |
| Non-cashlease expense | 464 | 306 |
| Loss from equity method investment | 0 | - |
| Loss on impairment of equity investment | 74 | 74 |
| Change in fair value of cvr liability | 374 | 374 |
| Change in fair value of convertible notes | 0 | - |
| Prepaid expenses and other current assets | -2,141 | -420 |
| Other noncurrent assets | -116 | 454 |
| Accounts payable | -2,016 | -2,079 |
| Operating lease liability | -455 | -300 |
| Accrued expenses and other current liabilities | -3,634 | -3,123 |
| Net cash used in operating activities | -27,363 | -23,133 |
| Purchases of property and equipment | 0 | 0 |
| Maturities of short-term investments | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 |
| Proceeds from borrowings under loan and security agreement | 0 | 0 |
| Proceeds from issuance of common stock in pre-closing financing | 0 | 0 |
| Cash acquired in connection with reverse recapitalization | 0 | 0 |
| Payment of reverse recapitalization transaction costs | 0 | 0 |
| Principal payments on venture debt | -1,563 | - |
| Proceeds from exercise of common stock options | 0 | 0 |
| Net cash (used in) provided by financing activities | -1,563 | 0 |
| Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | -28,926 | -23,133 |
| Cash and cash equivalents at beginning of period | 78,612 | - |
| Cash and cash equivalents at end of period | 49,686 | - |
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)